Meta Platforms (NASDAQ: META) and Eli Lilly and Company (NYSE: LLY) are identified as potential candidates for stock splits due to their high share prices and strong recent performance. As of June 13, 2024, Meta’s share price is approximately $683, reflecting a 315% increase over three years, while Lilly’s shares are trading at about $819, with a 176% increase in the same period. Only 45 stocks in the Russell 1000 Index surpass the $500 price point, highlighting the rarity of such valuations.
Meta is particularly notable for being one of the “Magnificent Seven” stocks that has not yet announced a stock split, while it ranks as the sixth-most-owned stock among retail investors, accounting for 3.7% of retail portfolios as of December 17, 2024. Eli Lilly’s market presence in the weight loss sector, notably with its Zepbound drug, could further boost retail interest, especially as nearly 75% of American adults are classified as obese or overweight according to a study from The Lancet.
